![Beyond morphology: FDA mulls acute lymphoblastic leukemia drug based on elimination of “minimal residual disease”](https://cdn.cancerletter.com/media/2018/03/odac-web.png)
![Beyond morphology: FDA mulls acute lymphoblastic leukemia drug based on elimination of “minimal residual disease”](https://cdn.cancerletter.com/media/2018/03/odac-web.png)
Cover Story
Free
The FDA Oncologic Drugs Advisory Committee March 7 voted to accept the metric of “minimal residual disease,” or MRD, as a basis for approval of a drug for the treatment of acute lymphoblastic leukemia.
In Brief
Funding Opportunities
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.